Tak Paul Peter
SEC CIK 1873905 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| CADL | Candel Therapeutics, Inc. | CEO, Dir | 113.3K | $230.0K | $4.21M | 15 | 2021-07-29 | 2026-09-10 |
Most active insiders at CADL, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Tak Paul Peter | CEO, Dir | — | $3.16M |
| 2 | Manning Paul B | Dir | $3.00M | — |
| 3 | Barone Francesca | CSO | — | $235.8K |
| 4 | Tyagarajan Seshu | CTO | — | $154.2K |
Transactions 15
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-11 18:12 | 2026-09-10 | CADL | Candel Therapeutics, Inc. | Tak Paul Peter | CEO, Dir | M - OptEx | $1.55 | +125.0K | 393.6K | +47% | +$193.8K |
| DMT | 2026-09-11 18:12 | 2026-09-10+ | CADL | Candel Therapeutics, Inc. | Tak Paul Peter | CEO, Dir | S - Sale+OE | $11.28 | -280.2K | 113.3K | -71% | -$3.16M |
| 2025-06-26 | 2025-06-25 | CADL | Candel Therapeutics, Inc. | Tak Paul Peter | CEO, Dir | A - Grant | $4.67 | +42.8K | 268.6K | +19% | +$200.0K | |
| MT | 2025-03-20 | 2025-03-18+ | CADL | Candel Therapeutics, Inc. | Tak Paul Peter | CEO, Dir | S - Sale | $8.77 | -26.2K | 226.1K | -10% | -$229.6K |
| 2025-01-17 | 2025-01-15 | CADL | Candel Therapeutics, Inc. | Tak Paul Peter | CEO, Dir | S - Sale | $7.23 | -21.7K | 251.9K | -8% | -$156.9K | |
| 2025-01-10 | 2025-01-08 | CADL | Candel Therapeutics, Inc. | Tak Paul Peter | CEO, Dir | S - Sale | $8.22 | -21.2K | 273.6K | -7% | -$174.0K | |
| 2024-12-03 | 2024-11-29 | CADL | Candel Therapeutics, Inc. | Tak Paul Peter | CEO, Dir | S - Sale | $4.56 | -48.8K | 294.8K | -14% | -$222.7K | |
| D | 2024-11-21 | 2024-11-21 | CADL | Candel Therapeutics, Inc. | Tak Paul Peter | CEO, Dir | M - OptEx | $1.55 | +12.9K | 343.6K | +4% | +$20.0K |
| 2024-07-19 | 2024-07-17 | CADL | Candel Therapeutics, Inc. | Tak Paul Peter | CEO, Dir | S - Sale | $6.47 | -22.5K | 330.7K | -6% | -$145.8K | |
| 2024-07-15 | 2024-07-11 | CADL | Candel Therapeutics, Inc. | Tak Paul Peter | CEO, Dir | S - Sale | $5.97 | -20.3K | 353.3K | -5% | -$121.1K | |
| 2023-11-30 | 2023-11-28 | CADL | Candel Therapeutics, Inc. | Tak Paul Peter | CEO, Dir | F - Tax | $0.9 | -43.4K | 373.6K | -10% | -$39.1K | |
| 2023-11-28 | 2023-11-26 | CADL | Candel Therapeutics, Inc. | Tak Paul Peter | CEO, Dir | A - Grant | $0.00 | +180.1K | 417.0K | +76% | $0 | |
| M | 2022-12-12 | 2022-12-08+ | CADL | Candel Therapeutics, Inc. | Tak Paul Peter | CEO, Dir | P - Purchase | $1.88 | +16.0K | 28.1K | +132% | +$30.0K |
| 2022-11-30 | 2022-11-28 | CADL | Candel Therapeutics, Inc. | Tak Paul Peter | CEO, Dir | A - Grant | $0.00 | +195.9K | 220.9K | +784% | $0 | |
| 2021-08-02 | 2021-07-29 | CADL | Candel Therapeutics, Inc. | Tak Paul Peter | CEO, Dir | P - Purchase | $8.00 | +25.0K | 25.0K | New | +$200.0K |
Purchase Sale Sale after option exercise All abbreviations